DAINIPPON SUMITOMO– PREVAIL TRIAL DATA: Latuda Will Pave A Way For Bipolar Disorder As Well!
Top line data from PREVAIL I & II trials announced on 24 April, 2012, show Latuda (lurasidone, already approved for Schizophrenia) meeting statistical significance for efficacy in adjuvant therapy with lithium or valproate and as monotherapy respectively for Bipolar Disorder I. Top line data suggests that safety was found to be consistence in all trials and in acceptable range. This report analysis key findings from PREVAIL I & II studies and Latuda positioning in bi-polar disorder space.
COMPANIES MENTIONED
DAINIPPON SUMITOMO
DAINIPPON SUMITOMO
